Toward a complete dataset of drug-drug interaction information from publicly available sources

Journal of Biomedical Informatics

Volumn 55, Issue , 2015, Pages 206-217

  Ayvaz, Serkan ^a   Horn, John ^b   Hassanzadeh, Oktie ^c   Zhu, Qian ^d   Stan, Johann ^e   Tatonetti, Nicholas P ^f   Vilar, Santiago ^f   Brochhausen, Mathias ^g   Samwald, Matthias ^h   Rastegar Mojarad, Majid ⁱ   Dumontier, Michel ^j   Boyce, Richard D ^k  

^a KENT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c IBM T J WATSON RESEARCH CENTER   (United States)

^d University of Marylandw Baltimore County   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ MAYO CLINIC   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Department of Biomedical Informatics ^*  (United States)

more..

Author keywords

Drug drug interaction; Natural language processing; Pharmacovigilance; Record linkage

Indexed keywords

DATA HANDLING; EXTRACTION; LINGUISTICS; NATURAL LANGUAGE PROCESSING SYSTEMS; TEXT MINING;

CLINICAL SETTINGS; DRUG-DRUG INTERACTIONS; IDENTIFYING METHODS; INFORMATION SOURCES; NATURAL LANGUAGE PROCESSING; PHARMACOVIGILANCE; PRODUCT LABELING; RECORD LINKAGE;

DRUG INTERACTIONS;

ALGORITHM; ARTICLE; COMPUTER LANGUAGE; COMPUTER PROGRAM; DATA BASE; DRUG MARKETING; DRUG PACKAGING; DRUG SURVEILLANCE PROGRAM; INFORMATION PROCESSING; MEDICAL RECORD; POTENTIAL DRUG DRUG INTERACTION DATABASE; PRIORITY JOURNAL; DATA MINING; DATABASE MANAGEMENT SYSTEM; DRUG INTERACTION; FACTUAL DATABASE; INTERNET; MACHINE LEARNING; NATURAL LANGUAGE PROCESSING; ORGANIZATION AND MANAGEMENT; PROCEDURES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA MINING; DATABASE MANAGEMENT SYSTEMS; DATABASES, FACTUAL; DRUG INTERACTIONS; INTERNET; MACHINE LEARNING; MEDICAL RECORD LINKAGE; NATURAL LANGUAGE PROCESSING; PHARMACOVIGILANCE;

EID: 84930706290     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2015.04.006     Document Type: Article

References (51)

1. Hines L.E., Malone D.C., Murphy J.E. Recommendations for generating, evaluating, and implementing drug-drug interaction evidence. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2012, 32(4):304-313.
2. R. Scheife, L.E. Hines, R. Boyce, S. Chung, J. Momper, C. Sommer, D. Abernethy, J. Horn, S. Sklar, S. Wong, G. Jones, M. Brown, A. Grizzle, S. Comes, T. Wilkins, T. Borst, M. Wittie, A. Rich, D. Malone, Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support, Drug Saf., 2015.
3. Nebeker J.R., Barach P., Samore M.H. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann. Intern. Med. 2004, 140(10):795-801.
4. Hines L.E., Murphy J.E. Potentially harmful drug-drug interactions in the elderly: a review. Am. J. Geriatr. Pharmacother. Dec. 2011, 9(6):364-377.
5. FASTSTATS - Emergency Department Visits, 23-Sep-2013. <> (accessed 24.09.13). http://www.cdc.gov/nchs/fastats/ervisits.htm.
6. Magro L., Moretti U., Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin. Drug Saf. Jan. 2012, 11(1):83-94.
7. Wang L.M., Wong M., Lightwood J.M., Cheng C.M. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann. Pharmacother. 2010, 44(1):28-34.
8. Boyce R.D., Collins C., Clayton M., Kloke J., Horn J.R. Inhibitory metabolic drug interactions with newer psychotropic drugs: inclusion in package inserts and influences of concurrence in drug interaction screening software. Ann. Pharmacother. 2012, 46(10):1287-1298.
9. CMS, Eligible Professional Meaningful Use Core Measures Measure 2 of 15, Centers for Medicare and Medicaid Services, 2010.
10. Ridgely M.S., Greenberg M.D. Too many alerts, too much liability: sorting through the malpractice implications of drug-drug interaction clinical decision support. St. Louis Univ. J. Health Law Policy 2012, 5(2):257-296.
11. Cami A., Manzi S., Arnold A., Reis B.Y. Pharmacointeraction network models predict unknown drug-drug interactions. PLoS One 2013, 8(4):e61468.
12. Azuaje F. Drug interaction networks: an introduction to translational and clinical applications. Cardiovasc. Res. Mar. 2013, 97(4):631-641.
13. Vandervalk B., McCarthy E.L., Cruz-Toledo J., Klein A., Baker C.J.O., Dumontier M., et al. The SADI personal health lens: a web browser-based system for identifying personally relevant drug interactions. JMIR Res. Protoc. 2013, 2(1):e14.
14. Vilar S., Uriarte E., Santana L., Lorberbaum T., Hripcsak G., Friedman C., et al. Similarity-based modeling in large-scale prediction of drug-drug interactions. Nat. Protoc. 2014, 9(9):2147-2163.
15. Tatonetti N.P., Ye P.P., Daneshjou R., Altman R.B. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 2012, 4(125):125ra31.
16. Belleau F., Nolin M.-A., Tourigny N., Rigault P., Morissette J. Bio2RDF: towards a mashup to build bioinformatics knowledge systems. J. Biomed. Inform. 2008, 41(5):706-716.
17. Law V., Knox C., Djoumbou Y., Jewison T., Guo A.C., Liu Y., et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014, 42(January):D1091-1097. (Database issue).
18. Bui Q.-C., Sloot P.M.A., van Mulligen E.M., Kors J.A. A novel feature-based approach to extract drug-drug interactions from biomedical text. Bioinf. Oxf. Engl. 2014, 30(23):3365-3371.
19. Hines L.E., Ceron-Cabrera D., Romero K., Anthony M., Woosley R.L., Armstrong E.P., et al. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin. Ther. Jan. 2011, 33(1):36-45.
20. Pfistermeister B., Saß A., Criegee-Rieck M., Bürkle T., Fromm M.F., Maas R. Inconsistencies and misleading information in officially approved prescribing information from three major drug markets. Clin. Pharmacol. Ther. 2014, 96(5):616-624.
21. Boyce R.D., Horn J.R., Hassanzadeh O., de Waard A., Schneider J., Luciano J.S., et al. Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J. Biomed. Semant. 2013, 4(1):5.
22. Olvey E.L., Clauschee S., Malone D.C. Comparison of critical drug-drug interaction listings: the department of Veterans Affairs medical system and standard reference compendia. Clin. Pharmacol. Ther. 2010, 87(1):48-51.
23. Crediblemeds.org, 05-Oct-2013. <> (accessed 05.10.13). http://www.crediblemeds.org/.
24. Phansalkar S., Desai A.A., Bell D., Yoshida E., Doole J., Czochanski M., et al. High-priority drug-drug interactions for use in electronic health records. J. Am. Med. Inform. Assoc. JAMIA 2012, 19(5):735-743.
25. Phansalkar S., van der Sijs H., Tucker A.D., Desai A.A., Bell D.S., Teich J.M., et al. Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. J. Am. Med. Inform. Assoc. JAMIA 2013, 20(3):489-493.
26. Crowther N.R., Holbrook A.M., Kenwright R., Kenwright M. Drug interactions among commonly used medications. Chart simplifies data from critical literature review. Can. Fam. Physician Médecin Fam. Can. 1997, 43(November):1972-1976. (1979-1981).
27. Oscar-McMaster, OSCAR Electronic Medical Record,OSCAREMR, 2014. <> (accessed 13.10.14). http://oscar-emr.com/.
28. I. Segura-Bedmar, P. Martinez, D. Sánchez-Cisneros, The 1st DDIExtraction-2011 challenge task: Extraction of Drug-Drug Interactions from biomedical texts, 2011.
29. I. Segura-Bedmar, P. Martinez, and M. Herrero-Zazo, Semeval-2013 task 9: extraction of drug-drug interactions from biomedical texts, in: Proceedings of the 7th International Workshop on Semantic Evaluation (SemEval 2013), 2013.
30. R. Boyce, G. Gardner, and H. Harkema, Using natural language processing to extract drug-drug interaction information from package inserts, in: BioNLP: Proceedings of the 2012 Workshop on Biomedical Natural Language Processing, Montréal, Canada, 2012, pp. 206-213.
31. Johann Stan, A Machine-Learning Approach for Drug-Drug Interaction Extraction from FDA Structured Product Labels, Presented at the 2014 National Library of Medicine Training Conference, Pittsburgh PA, USA, 17-Jun-2014.
32. Takarabe M., Shigemizu D., Kotera M., Goto S., Kanehisa M. Network-based analysis and characterization of adverse drug-drug interactions. J. Chem. Inf. Model. 2011, 51(11):2977-2985.
33. Kanehisa M., Goto S., Sato Y., Kawashima M., Furumichi M., Tanabe M., et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014, 42(January):D199-205. (Database issue).
34. Boyce R., Collins C., Horn J., Kalet I. Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions. J. Biomed. Inform. 2009, 42(6):990-1003.
35. Kilicoglu H., Shin D., Fiszman M., Rosemblat G., Rindflesch T.C. SemMedDB: a PubMed-scale repository of biomedical semantic predications. Bioinformatics 2012, 28(23):3158-3160.
36. Horn J.R., Hansten P.D., Chan L.-N. Proposal for a new tool to evaluate drug interaction cases. Ann. Pharmacother. Apr. 2007, 41(4):674-680.
37. L. Peters, O. Bodenreider, N. Bahr, Evaluating drug-drug interaction information in NDF-RT and DrugBank, in: Proceedings of the Workshop on Vaccines and Drug Ontology Studies (VDOS-2014), Houston, Texas, 2014.
38. RxNorm, 2014. <> (accessed 16.10.14). http://www.nlm.nih.gov/research/umls/rxnorm/.
39. RxNorm Documentation, 2014. <> (accessed 16.10.14). http://www.nlm.nih.gov/research/umls/rxnorm/docs/2012/rxnorm_doco_full_2012-3.html#s8_0.
40. O. Hassanzadeh, Q. Zhu, R. Freimuth, R. Boyce, Extending the 'Web of Drug Identity' with knowledge extracted from United States product labels, in: Proc. 2013 AMIA Summit Transl. Bioinforma., Mar. 2013.
41. InChI, 2014. <> (accessed 16.10.14). http://www.iupac.org/home/publications/e-resources/inchi.html.
42. Defalco F.J., Ryan P.B., Soledad Cepeda M. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Heal Serv. Outcomes Res. Methodol. 2013, 13(1):58-67.
43. Zhu Q., Jiang G., Chute C.G. Profiling structured product labeling with NDF-RT and RxNorm. J. Biomed. Semant. 2012, 3(1):16.
44. Hazlet T.K., Lee T.A., Hansten P.D., Horn J.R. Performance of community pharmacy drug interaction software. J. Am. Pharm. Assoc. 2001, 41(2):200-204. (Washington, DC 1996).
45. W.R. Hogan, J. Hanna, E. Joseph, M. Brochhausen, Towards a consistent and scientifically accurate drug ontology, in: ICBO 2013 Conference Proceedings, 2013.
46. M. Brochhausen, J. Schneider, D. Malone, P. Empey, W.R. Hogan, R.D. Boyce, Towards a foundational representation of potential drugdrug interaction knowledge, in: Drug Interaction Knowledge Representation (DIKR 2014), Houston, Texas, 2014.
47. Wikidata, <> (accessed 05.10.13). http://www.wikidata.org/wiki/Wikidata:Main_Page.
48. Kritz M., Gschwandtner M., Stefanov V., Hanbury A., Samwald M. Utilization and perceived problems of online medical resources and search tools among different groups of European physicians. J. Med. Internet Res. Jun. 2013, 15(6):e122.
49. Heilman J.M., Kemmann E., Bonert M., Chatterjee A., Ragar B., Beards G.M., et al. Wikipedia: a key tool for global public health promotion. J. Med. Internet Res. Jan. 2011, 13(1):e14.
50. Clauson K.A., Polen H.H., Boulos M.N.K., Dzenowagis J.H. Scope, completeness, and accuracy of drug information in Wikipedia. Ann. Pharmacother. Dec. 2008, 42(12):1814-1821.
51. Richard D. Boyce, The Drug Interaction Knowledge Base, 2014. <> (accessed 14.10.14). http://purl.org/net/drug-interaction-knowledge-base/.